| 1 | High-Risk Embolic Sources on Cardiac Computed Tomography in Patients With Acute Ischemic Stroke: A Case-Control Study | 6.2 | 0 | Citations (PDF) |
| 2 | Long-term cardiac follow-up of athletes infected with SARS-CoV-2 after resumption of elite-level sportsHeart, 2024, 110, 254-262 | 2.8 | 1 | Citations (PDF) |
| 3 | Long‐Term Clinical Implications of High‐Risk Cardiac Computed Tomography Findings in Patients With Acute Ischemic Stroke | 4.3 | 1 | Citations (PDF) |
| 4 | Constrictive Pericarditis Caused by Primary Pericardial Mesothelioma: A Case Series | 3.2 | 0 | Citations (PDF) |
| 5 | Left Atrial Appendage Opacification on Cardiac Computed Tomography in Acute Ischemic Stroke: The Clinical Implications of Slow‐Flow | 4.3 | 4 | Citations (PDF) |
| 6 | Genetic Variance in Heparan Sulfation Is Associated With Salt Sensitivity | 7.0 | 0 | Citations (PDF) |
| 7 | ELITE: rationale and design of a longitudinal elite athlete, extreme cardiovascular phenotyping, prospective cohort study | 2.4 | 2 | Citations (PDF) |
| 8 | Impact of C-reactive protein levels on lipoprotein(a)-associated aortic stenosis incidence and progression | 2.8 | 3 | Citations (PDF) |
| 9 | Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels | 4.2 | 7 | Citations (PDF) |
| 10 | ANGPTL3 (Angiopoietin‐Like 3) Preferentially Resides on High‐Density Lipoprotein in the Human Circulation, Affecting Its Activity | 4.3 | 3 | Citations (PDF) |
| 11 | Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis | 2.8 | 23 | Citations (PDF) |
| 12 | Baffle Complications in Adults After Atrial Switch for Transposition of the Great Arteries | 1.9 | 3 | Citations (PDF) |
| 13 | Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et alHeart, 2022, 108, 576-577 | 2.8 | 0 | Citations (PDF) |
| 14 | Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC‐Norfolk prospective population‐based cohort study | 2.8 | 10 | Citations (PDF) |
| 15 | Standardizing the Cardiac Radioablation Targeting Workflow: Enabling Semi-Automated Angulation and Segmentation of the Heart According to the American Heart Association Segmented Model | 1.4 | 16 | Citations (PDF) |
| 16 | Confirmatory factor analysis including MRI-derived adipose tissues quantification improves associations of metabolic dysregulation to diastolic dysfunction | 2.6 | 1 | Citations (PDF) |
| 17 | Relationship of Sodium Intake With Granulocytes, Renal and Cardiovascular Outcomes in the Prospective EPIC‐Norfolk Cohort | 4.3 | 1 | Citations (PDF) |
| 18 | Association of Circulating Monocyte Chemoattractant Protein–1 Levels With Cardiovascular Mortality | 9.7 | 39 | Citations (PDF) |
| 19 | Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy | 3.7 | 14 | Citations (PDF) |
| 20 | Fully quantitative mapping of abnormal aortic velocity and wall shear stress direction in patients with bicuspid aortic valves and repaired coarctation using 4D flow cardiovascular magnetic resonance | 4.7 | 18 | Citations (PDF) |
| 21 | Retrospective Camera‐Based Respiratory Gating in Clinical Whole‐Heart <scp>4D</scp> Flow <scp>MRI</scp> | 3.7 | 9 | Citations (PDF) |
| 22 | Multimodality Evaluation of a Septal Cystic Cavity and Ventricular Septal Defect in the Setting of Neurocysticercosis and Endocarditis | 3.2 | 0 | Citations (PDF) |
| 23 | Lipoprotein(a) is robustly associated with aortic valve calciumHeart, 2021, 107, 1422-1428 | 2.8 | 40 | Citations (PDF) |
| 24 | Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study | 2.9 | 47 | Citations (PDF) |
| 25 | Association between serum secretory phospholipase A2 and risk of ischaemic stroke | 3.7 | 2 | Citations (PDF) |
| 26 | Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic
<i>LPA</i>
Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses | 3.2 | 16 | Citations (PDF) |
| 27 | Impact of cholesterol on proinflammatory monocyte production by the bone marrow | 2.2 | 43 | Citations (PDF) |
| 28 | Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect | 16.3 | 172 | Citations (PDF) |
| 29 | Aortic dissection masquerading as a code stroke: A single-centre cohort study | 4.1 | 9 | Citations (PDF) |
| 30 | Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention | 2.2 | 76 | Citations (PDF) |
| 31 | Mind the Heart: Electrocardiography-gated cardiac computed tomography-angiography in acute ischaemic stroke—rationale and study design | 4.1 | 7 | Citations (PDF) |
| 32 | Quantification of Mitral Valve Regurgitation from 4D Flow MRI Using Semiautomated Flow Tracking | 3.1 | 19 | Citations (PDF) |
| 33 | Subclinical effects of long‐chain fatty acid β‐oxidation deficiency on the adult heart: A case‐control magnetic resonance study | 3.4 | 11 | Citations (PDF) |
| 34 | CT angiography vs echocardiography for detection of cardiac thrombi in ischemic stroke: a systematic review and meta-analysis | 3.4 | 32 | Citations (PDF) |
| 35 | Genetic and In Vitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis | 3.5 | 54 | Citations (PDF) |
| 36 | Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humansHeart, 2020, 106, 1407-1412 | 2.8 | 15 | Citations (PDF) |
| 37 | Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease–Free Survival, and Mortality Risk | 7.2 | 33 | Citations (PDF) |
| 38 | Outcomes of cardiac surgery after mediastinal radiation therapy: A single‐center experience | 0.9 | 13 | Citations (PDF) |
| 39 | A pooled-analysis of age and sex based coronary artery calcium scores percentiles | 1.2 | 14 | Citations (PDF) |
| 40 | Association of <i>FADS1/2</i> Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis | 9.7 | 36 | Citations (PDF) |
| 41 | Lifestyle modification in older versus younger patients with coronary artery diseaseHeart, 2020, 106, 1066-1072 | 2.8 | 16 | Citations (PDF) |
| 42 | apoB/apoA‐I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC‐Norfolk Prospective Population Study | 4.3 | 18 | Citations (PDF) |
| 43 | Validation of the Systematic COronary Risk Evaluation - Older Persons (SCORE-OP) in the EPIC-Norfolk prospective population study | 2.2 | 10 | Citations (PDF) |
| 44 | Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke | 12.8 | 81 | Citations (PDF) |
| 45 | Genetic Variation in <i>LPA</i>, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification | 9.7 | 39 | Citations (PDF) |
| 46 | Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis | 2.6 | 221 | Citations (PDF) |
| 47 | A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk | 2.0 | 4 | Citations (PDF) |
| 48 | Abnormal blood flow and wall shear stress are present in corrected aortic coarctation despite successful surgical repair | 0.8 | 4 | Citations (PDF) |
| 49 | Bileaflet mechanical aortic valves do not alter ascending aortic wall shear stress | 1.3 | 9 | Citations (PDF) |
| 50 | Aortic dissection and prophylactic surgery in congenital heart disease | 2.2 | 14 | Citations (PDF) |
| 51 | Smoking cessation after nurse-coordinated referral to a comprehensive lifestyle programme in patients with coronary artery disease: a substudy of the RESPONSE-2 trial | 1.2 | 10 | Citations (PDF) |
| 52 | Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging | 1.4 | 47 | Citations (PDF) |
| 53 | Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial | 2.6 | 32 | Citations (PDF) |
| 54 | The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis | 2.9 | 22 | Citations (PDF) |
| 55 | Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease | 2.0 | 34 | Citations (PDF) |
| 56 | Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial | 19.4 | 141 | Citations (PDF) |
| 57 | Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery diseaseHeart, 2018, 104, 1699-1705 | 2.8 | 13 | Citations (PDF) |
| 58 | Aortic valve stenosis and aortic diameters determine the extent of increased wall shear stress in bicuspid aortic valve disease | 3.7 | 47 | Citations (PDF) |
| 59 | Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy | 2.6 | 250 | Citations (PDF) |
| 60 | Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk | 2.0 | 46 | Citations (PDF) |
| 61 | Impact of physical activity on the risk of cardiovascular disease in middle-aged and older adults: EPIC Norfolk prospective population study | 2.1 | 75 | Citations (PDF) |
| 62 | Effect of Losartan on Right Ventricular Dysfunction | 19.4 | 42 | Citations (PDF) |
| 63 | Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study | 2.0 | 7 | Citations (PDF) |
| 64 | Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting | 2.2 | 102 | Citations (PDF) |
| 65 | Life's simple 7 and calcific aortic valve stenosis incidence in apparently healthy men and women | 2.2 | 19 | Citations (PDF) |
| 66 | Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation | 1.8 | 8 | Citations (PDF) |
| 67 | Effect of Long-Term Low Lipoproteins on Neurocognitive Function | 2.6 | 2 | Citations (PDF) |
| 68 | Advanced cardiac MRI techniques for evaluation of left‐sided valvular heart disease | 3.7 | 37 | Citations (PDF) |
| 69 | Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk | 6.2 | 58 | Citations (PDF) |
| 70 | Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms | 2.6 | 33 | Citations (PDF) |
| 71 | An Evidence-Based Guide to Cholesterol-Lowering Guidelines | 1.9 | 17 | Citations (PDF) |
| 72 | Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration | 2.5 | 5 | Citations (PDF) |
| 73 | Association of High‐Density Lipoprotein‐Cholesterol Versus Apolipoprotein A‐I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer‐Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study | 4.3 | 14 | Citations (PDF) |
| 74 | Coronary Artery Disease Affects Symptomatology of Aortic Valve Stenosis | 2.6 | 1 | Citations (PDF) |
| 75 | Systolic anterior motion of the tricuspid valve in a patient with hypertrophic obstructive cardiomyopathy | 1.5 | 2 | Citations (PDF) |
| 76 | Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease | 2.6 | 72 | Citations (PDF) |
| 77 | Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study | 1.2 | 80 | Citations (PDF) |
| 78 | Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief Report | 6.2 | 24 | Citations (PDF) |
| 79 | Very low LDL-cholesterol concentrations achieved: which target is next? | 35.3 | 3 | Citations (PDF) |
| 80 | Human Cardiac 31P-MR Spectroscopy at 3 Tesla Cannot Detect Failing Myocardial Energy Homeostasis during Exercise | 3.0 | 30 | Citations (PDF) |
| 81 | Four-dimensional flow MRI of stented versus stentless aortic valve bioprostheses | 3.8 | 14 | Citations (PDF) |
| 82 | Meta-analysis of genome-wide association studies of HDL cholesterol response to statins | 3.7 | 30 | Citations (PDF) |
| 83 | Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations | 2.6 | 27 | Citations (PDF) |
| 84 | Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus | 4.5 | 12 | Citations (PDF) |
| 85 | Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population | 19.4 | 192 | Citations (PDF) |
| 86 | Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study | 3.7 | 29 | Citations (PDF) |
| 87 | C‐Reactive Protein Identifies Low‐Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer–Norfolk Prospective Population Study | 4.3 | 21 | Citations (PDF) |
| 88 | Effective components of nurse-coordinated care to prevent recurrent coronary events: a systematic review and meta-analysis | 2.8 | 33 | Citations (PDF) |
| 89 | Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus | 0.8 | 49 | Citations (PDF) |
| 90 | Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease | 1.2 | 8 | Citations (PDF) |
| 91 | Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study | 2.2 | 38 | Citations (PDF) |
| 92 | Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk | 2.8 | 46 | Citations (PDF) |
| 93 | Ideal cardiovascular health and risk of cardiovascular events in the EPIC-Norfolk prospective population study | 2.1 | 65 | Citations (PDF) |
| 94 | Non-high-density lipoprotein cholesterol | 4.1 | 71 | Citations (PDF) |
| 95 | The Systematic COronary Risk Evaluation (SCORE) in a large UK population: 10-year follow-up in the EPIC-Norfolk prospective population study | 2.1 | 23 | Citations (PDF) |
| 96 | Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study | 22.3 | 397 | Citations (PDF) |
| 97 | <i>PLA2G10</i>
Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk | 4.2 | 17 | Citations (PDF) |
| 98 | Reply | 2.6 | 0 | Citations (PDF) |
| 99 | Habitual chocolate consumption and risk of cardiovascular disease among healthy men and womenHeart, 2015, 101, 1279-1287 | 2.8 | 65 | Citations (PDF) |
| 100 | Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? | 19.4 | 28 | Citations (PDF) |
| 101 | Community-based comprehensive lifestyle programs in patients with coronary artery disease: Objectives, design and expected results of Randomized Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists 2 trial (RESPONSE 2) | 2.9 | 13 | Citations (PDF) |
| 102 | Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins | 14.1 | 202 | Citations (PDF) |
| 103 | Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis | 4.2 | 232 | Citations (PDF) |
| 104 | Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women | 1.2 | 8 | Citations (PDF) |
| 105 | The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011 | 2.2 | 261 | Citations (PDF) |
| 106 | Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL) | 1.9 | 26 | Citations (PDF) |
| 107 | The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal? | 0.5 | 82 | Citations (PDF) |
| 108 | Added value of hybrid myocardial perfusion SPECT and CT coronary angiography in the diagnosis of coronary artery disease | 1.4 | 31 | Citations (PDF) |
| 109 | Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA
<sub>2</sub>
)-V Isoenzyme in Coronary Heart Disease | 4.2 | 22 | Citations (PDF) |
| 110 | Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events | 2.6 | 509 | Citations (PDF) |
| 111 | Secretory Phospholipase A2-IIA and Cardiovascular Disease | 2.6 | 106 | Citations (PDF) |
| 112 | Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients | 19.4 | 170 | Citations (PDF) |
| 113 | Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions | 2.8 | 35 | Citations (PDF) |
| 114 | Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study | 2.2 | 5 | Citations (PDF) |
| 115 | Response to letter by Balta et al. | 2.2 | 2 | Citations (PDF) |
| 116 | Rates and determinants of progressive aortic valve dysfunction in aortic coarctation | 2.2 | 5 | Citations (PDF) |
| 117 | Reply | 2.6 | 5 | Citations (PDF) |
| 118 | Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC—Norfolk study | 2.2 | 57 | Citations (PDF) |
| 119 | Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy | 2.6 | 153 | Citations (PDF) |
| 120 | Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease | 1.4 | 44 | Citations (PDF) |
| 121 | Title is missing!Heart, 2013, 99, 1136.2-1137 | 2.8 | 2 | Citations (PDF) |
| 122 | C-Reactive Protein, Fatal and Nonfatal Coronary Artery Disease, Stroke, and Peripheral Artery Disease in the Prospective EPIC-Norfolk Cohort Study | 6.2 | 42 | Citations (PDF) |
| 123 | A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort | 2.1 | 3 | Citations (PDF) |
| 124 | High-sensitivity Troponin T Is Associated with Poor Outcome in Adults with Pulmonary Arterial Hypertension due to Congenital Heart Disease | 0.5 | 34 | Citations (PDF) |
| 125 | Non‐<scp>HDL</scp> cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the <scp>EPIC</scp>‐Norfolk prospective population study | 3.2 | 25 | Citations (PDF) |
| 126 | High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease | 19.4 | 36 | Citations (PDF) |
| 127 | Common genetic variants do not associate with CAD in familial hypercholesterolemia | 3.1 | 3 | Citations (PDF) |
| 128 | Clinical and Biological Relevance of Statin-Mediated Changes in HDL Metabolism | 4.9 | 6 | Citations (PDF) |
| 129 | The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies | 4.2 | 20 | Citations (PDF) |
| 130 | Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | 6.2 | 158 | Citations (PDF) |
| 131 | Relationship between atorvastatin dose and the harm caused by torcetrapib | 3.7 | 8 | Citations (PDF) |
| 132 | Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins | 13.7 | 636 | Citations (PDF) |
| 133 | Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy | 19.4 | 148 | Citations (PDF) |
| 134 | Lipid-Related Markers and Cardiovascular Disease Prediction | 13.7 | 337 | Citations (PDF) |
| 135 | Lipid Parameters and Cardiovascular Events in Patients Taking Statins—Reply | 13.7 | 0 | Citations (PDF) |
| 136 | De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough? | 2.2 | 6 | Citations (PDF) |
| 137 | The interleukin-6 pathway and atherosclerosis | 35.3 | 38 | Citations (PDF) |
| 138 | Surgical versus percutaneous treatment of aortic coarctation: new standards in an era of transcatheter repair | 1.8 | 35 | Citations (PDF) |
| 139 | On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy | 2.6 | 91 | Citations (PDF) |
| 140 | Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model | 7.4 | 11 | Citations (PDF) |
| 141 | Usefulness of coronary calcium scoring to myocardial perfusion SPECT in the diagnosis of coronary artery disease in a predominantly high risk population | 1.3 | 4 | Citations (PDF) |
| 142 | Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women | 2.2 | 92 | Citations (PDF) |
| 143 | Physical activity, metabolic syndrome, and coronary risk: the EPIC–Norfolk prospective population study | 2.8 | 47 | Citations (PDF) |
| 144 | Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle? | 1.0 | 6 | Citations (PDF) |
| 145 | Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease | 16.3 | 1,542 | Citations (PDF) |
| 146 | Adiponectin and Risk of Coronary Heart Disease in Apparently Healthy Men and Women (from the EPIC-Norfolk Prospective Population Study) | 1.9 | 33 | Citations (PDF) |
| 147 | Varespladib: targeting the inflammatory face of atherosclerosis | 2.2 | 7 | Citations (PDF) |
| 148 | Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study | 3.7 | 114 | Citations (PDF) |
| 149 | Lipid parameters for measuring risk of cardiovascular disease | 12.5 | 174 | Citations (PDF) |
| 150 | The Authors' reply | 2.8 | 0 | Citations (PDF) |
| 151 | The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease | 4.9 | 50 | Citations (PDF) |
| 152 | Comprehensive Lipid Profiling Beyond LDL 2011, , 107-118 | | 1 | Citations (PDF) |
| 153 | Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention | 1.3 | 7 | Citations (PDF) |
| 154 | Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol? | 1.8 | 7 | Citations (PDF) |
| 155 | Initial thyroid status and cardiovascular risk factors: The EPIC‐Norfolk prospective population study | 2.5 | 132 | Citations (PDF) |
| 156 | Lipid assessment, metabolic syndrome and coronary heart disease risk | 3.2 | 28 | Citations (PDF) |
| 157 | Biological, clinical and population relevance of 95 loci for blood lipids | 40.1 | 2,933 | Citations (PDF) |
| 158 | Genetic Variation at the
<i>Phospholipid Transfer Protein</i>
Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility | 19.4 | 81 | Citations (PDF) |
| 159 | Chemokine Ligand 2 Genetic Variants, Serum Monocyte Chemoattractant Protein-1 Levels, and the Risk of Coronary Artery Disease | 6.2 | 18 | Citations (PDF) |
| 160 | <i>PLA2G7</i>
Genotype, Lipoprotein-Associated Phospholipase A
<sub>2</sub>
Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry | 19.4 | 98 | Citations (PDF) |
| 161 | Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With
<i>CETP</i>
Gene Polymorphisms | 19.4 | 84 | Citations (PDF) |
| 162 | Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size | 1.1 | 33 | Citations (PDF) |
| 163 | The Relationship Between Plasma Angiopoietin-like Protein 4 Levels, Angiopoietin-like Protein 4 Genotype, and Coronary Heart Disease Risk | 6.2 | 65 | Citations (PDF) |
| 164 | Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease | 6.2 | 349 | Citations (PDF) |
| 165 | The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population StudyCmaj, 2010, 182, 1427-1432 | 1.4 | 142 | Citations (PDF) |
| 166 | Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events | 2.6 | 130 | Citations (PDF) |
| 167 | Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study | 2.2 | 30 | Citations (PDF) |
| 168 | Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study | 1.2 | 28 | Citations (PDF) |
| 169 | Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT | 1.2 | 35 | Citations (PDF) |
| 170 | C-reactive protein and cardiovascular risk: more fuel to the fire | 35.3 | 22 | Citations (PDF) |
| 171 | C-reactive protein measurement and cardiovascular disease – Authors' reply | 35.3 | 1 | Citations (PDF) |
| 172 | HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial | 35.3 | 208 | Citations (PDF) |
| 173 | Rimonabant: obituary for a wonder drug | 35.3 | 17 | Citations (PDF) |
| 174 | C-reactive protein is a mediator of cardiovascular disease | 2.2 | 162 | Citations (PDF) |
| 175 | Improving risk stratification for cardiovascular disease | 1.8 | 3 | Citations (PDF) |
| 176 | Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population studyHeart, 2010, 96, 1985-1989 | 2.8 | 98 | Citations (PDF) |
| 177 | Both Paraoxonase-1 Genotype and Activity Do Not Predict the Risk of Future Coronary Artery Disease; the EPIC-Norfolk Prospective Population Study | 2.5 | 43 | Citations (PDF) |
| 178 | Retinol-Binding Protein 4 and Prediction of Incident Coronary Events in Healthy Men and Women | 4.4 | 50 | Citations (PDF) |
| 179 | Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-κB Ligand and Risk for Coronary Events | 6.2 | 69 | Citations (PDF) |
| 180 | Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women | 4.2 | 45 | Citations (PDF) |
| 181 | Is myeloperoxidase a useful marker to predict the risk of cardiovascular events? | 1.8 | 2 | Citations (PDF) |
| 182 | Beyond Low-Density Lipoprotein Cholesterol | 2.6 | 261 | Citations (PDF) |
| 183 | High-Density Lipoprotein Particle Size and Concentration and Coronary Risk | 10.5 | 199 | Citations (PDF) |
| 184 | HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study | 1.2 | 97 | Citations (PDF) |
| 185 | High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk | 2.6 | 310 | Citations (PDF) |
| 186 | <i>ANGPTL4</i>E40K and T266M | 6.2 | 86 | Citations (PDF) |
| 187 | Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment | 19.4 | 390 | Citations (PDF) |
| 188 | Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer–Norfolk Cohort<subtitle>Does Adding Glycated Hemoglobin Improve the Prediction of Coronary Heart Disease Events?</subtitle> | 8.9 | 65 | Citations (PDF) |
| 189 | Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib | 19.4 | 14 | Citations (PDF) |
| 190 | Major Depression, C-Reactive Protein, and Incident Ischemic Heart Disease in Healthy Men and Women | 2.3 | 29 | Citations (PDF) |
| 191 | Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease | 19.4 | 98 | Citations (PDF) |
| 192 | Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women | 6.2 | 88 | Citations (PDF) |
| 193 | Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study | 2.2 | 48 | Citations (PDF) |
| 194 | Arterial Thrombosis and the Role of Thrombophilia | 3.1 | 100 | Citations (PDF) |
| 195 | Triglycerides and the Risk of Coronary Heart Disease | 19.4 | 1,157 | Citations (PDF) |
| 196 | Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study | 3.7 | 105 | Citations (PDF) |
| 197 | Body Fat Distribution and Risk of Coronary Heart Disease in Men and Women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk Cohort | 19.4 | 386 | Citations (PDF) |
| 198 | Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk | 10.5 | 126 | Citations (PDF) |
| 199 | Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women | 2.6 | 217 | Citations (PDF) |
| 200 | Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals | 2.6 | 514 | Citations (PDF) |
| 201 | C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993–2003 | 1.2 | 135 | Citations (PDF) |
| 202 | Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study | 3.7 | 81 | Citations (PDF) |
| 203 | Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women | 6.2 | 59 | Citations (PDF) |
| 204 | Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels | 6.2 | 66 | Citations (PDF) |
| 205 | Physical activity, C-reactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC–Norfolk prospective population study | 2.8 | 19 | Citations (PDF) |
| 206 | Serum Lipoprotein Lipase Concentration and Risk for Future Coronary Artery Disease | 6.2 | 62 | Citations (PDF) |
| 207 | Inherited disorders of HDL metabolism and atherosclerosis | 4.1 | 87 | Citations (PDF) |
| 208 | Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women | 6.2 | 94 | Citations (PDF) |
| 209 | Relationship between In Vitro Lipopolysaccharide-Induced Cytokine Response in Whole Blood, Angiographic In-Stent Restenosis, and Toll-Like Receptor 4 Gene Polymorphisms | 1.1 | 11 | Citations (PDF) |
| 210 | Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women | 19.4 | 188 | Citations (PDF) |
| 211 | IL-8 Plasma Concentrations and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women | 6.2 | 161 | Citations (PDF) |
| 212 | Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events | 2.9 | 18 | Citations (PDF) |
| 213 | Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: The EPIC-Norfolk Prospective Population study | 2.1 | 75 | Citations (PDF) |
| 214 | CETP gene variation: relation to lipid parameters and cardiovascular risk | 4.1 | 58 | Citations (PDF) |
| 215 | Molecular variation at the apolipoprotein�B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis | 3.1 | 49 | Citations (PDF) |
| 216 | Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events | 19.4 | 200 | Citations (PDF) |
| 217 | Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease | 3.7 | 137 | Citations (PDF) |
| 218 | Thrombospondin-2 Polymorphism Is Associated With a Reduced Risk of Premature Myocardial Infarction | 6.2 | 61 | Citations (PDF) |
| 219 | Lipoprotein(a) and progression of aortic valve calcification: a case of collider bias? Reply | 2.2 | 1 | Citations (PDF) |
